Section of Cancer Epidemiology and Health Outcomes, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.
Department of Population Health Sciences, Weill Cornell Medical Center, New York, New York, USA.
Cancer Med. 2024 Nov;13(21):e70358. doi: 10.1002/cam4.70358.
Rising metastatic prostate cancer incidence has renewed debate regarding benefits of prostate-specific antigen (PSA) screening. Identifying barriers to accessing screening for individuals at high risk of lethal prostate cancer may slow this rise. We examined associations of access barriers with receipt of PSA testing, stratified by sociodemographic factors.
We pooled data from male respondents to Behavior Risk Factor Surveillance Systems (BRFSS) surveys from 2006 to 2020. Questions related to affordability (insurance, cost of visits) and accommodation (regular primary care provider (PCP), physician recommending a PSA test) were considered as individual-level barriers. For availability, we linked provider density from the 2012 Area Health Resource File and estimated driving times to closest health facility within Micropolitan and Metropolitan Statistical Area (MMSA) using Google Earth Engine. These measures were used to compute a spatial accessibility index. We fit survey-weighted, covariate-adjusted logistic regression models to estimate associations of barriers with receipt of PSA within the past 2 years and examined effect modification by sociodemographic factors.
There were 185,643 participants, of whom 73% were White, 11% were Black, 4% were Asian, and 11% were Hispanic. Physician recommendation was the strongest predictor of having a PSA test (aOR: 14.5, 95% CI: 13.6, 15.6). Not having a regular PCP (aOR: 0.29, 95% CI: 0.27, 0.31), insurance (aOR: 0.64, 95% CI: 0.58, 0.71), and prohibitive cost of care (aOR: 0.82, 95% CI: 0.75, 0.90) were associated with lower PSA testing. Access barriers were stronger predictors of PSA testing for Asian and White participants compared to other groups (P < 0.004 for insurance and regular PCP) and for those with college education compared to those without (P < 0.05 for insurance, perceived unaffordability).
Physician recommendation was the strongest predictor of receipt of PSA testing, regardless of sociodemographic grouping. Future studies should consider access barriers jointly and across sociodemographic strata.
不断上升的转移性前列腺癌发病率再次引发了关于前列腺特异性抗原(PSA)筛查益处的争论。识别高危致命性前列腺癌个体的筛查障碍可能会减缓这种上升趋势。我们通过社会人口统计学因素分层,研究了获得障碍与 PSA 检测接受率之间的关联。
我们从 2006 年至 2020 年的男性行为风险因素监测系统(BRFSS)调查中汇总了数据。可负担性(保险、就诊费用)和可及性(定期初级保健提供者(PCP)、医生推荐 PSA 检测)相关问题被视为个体层面的障碍。对于可及性,我们从 2012 年的区域卫生资源档案中链接了提供者密度,并使用谷歌地球引擎估计了到 Micropolitan 和大都市统计区(MMSA)内最近的卫生设施的驾驶时间。这些措施用于计算空间可及性指数。我们拟合了调查加权、协变量调整的逻辑回归模型,以估计过去 2 年内障碍与 PSA 检测接受率之间的关联,并检查了社会人口统计学因素的效应修饰作用。
共有 185643 名参与者,其中 73%为白人,11%为黑人,4%为亚洲人,11%为西班牙裔。医生的推荐是进行 PSA 检测的最强预测因素(优势比:14.5,95%置信区间:13.6,15.6)。没有定期的 PCP(优势比:0.29,95%置信区间:0.27,0.31)、保险(优势比:0.64,95%置信区间:0.58,0.71)和医疗费用过高(优势比:0.82,95%置信区间:0.75,0.90)与较低的 PSA 检测率相关。与其他群体相比(保险和定期 PCP 方面,P < 0.004;与没有大学学历的人相比,P < 0.05,保险、感知不可负担性方面),获得障碍对于亚裔和白人参与者来说是 PSA 检测的更强预测因素。
无论社会人口统计学分组如何,医生的推荐都是 PSA 检测接受率的最强预测因素。未来的研究应该联合考虑并跨越社会人口统计学阶层来考虑获得障碍。